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Abstract
Background: This study aimed to investigate the possible serum protein changes after endotoxin administration in
healthy and choline-treated calves using proteomics. These results are expected to contribute to the understanding
of the pathophysiological mechanisms of endotoxemia and the beneficial effect of choline administration in this
clinical situation.
Methods: Healthy-calves (n = 20) were divided into 4 groups: Control, Choline treated (C), Lipopolysaccharide
administered (LPS), and LPS + C. Control calves received 0.9 % NaCl injection. Calves in C and LPS + C groups received
choline chloride (1 mg/kg/iv). Endotoxin (LPS) was injected (2 μg/kg/iv) to the calves in LPS and LPS + C groups. Serum
samples were collected before and after the treatments. Differentially expressed proteins (> 1.5 fold-change relative to
controls) were identified by LC-MS/MS.
Results: After LPS administration, 14 proteins increased, and 13 proteins decreased within 48 h as compared to
controls. In the LPS group, there were significant increases in serum levels of ragulator complex protein (189-fold)
and galectin-3-binding protein (10-fold), but transcription factor MafF and corticosteroid binding globulin were
down regulated (≥ 5 fold). As compared with the LPS group, in LPS + C group, fibrinogen gamma-B-chain and
antithrombin were up-regulated, while hemopexin and histone H4 were down-regulated. Choline treatment
attenuated actin alpha cardiac muscle-1 overexpression after LPS.
Conclusions: LPS administration produces changes in serum proteins associated with lipid metabolism, immune
and inflammatory response, protein binding/transport, cell adhesion, venous thrombosis, cardiac contractility and
blood coagulation. The administration of choline is associated with changes in proteins which can be related
with its beneficial effect in this clinical situation.
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Background
Endotoxemia is defined as the presence of endotoxins
in blood. This situation can occur by Gram-negative
bacterial infections which liberate endotoxin (lipopoly-
saccharides; LPS) during rapid growth. This results in
the fact that Gram-negative sepsis is associated with
high mortality rates, despite comprehensive treatment
in intensive care patients [1]. Studies are underway with
regards to understanding the complex pathophysio-
logical mechanism of endotoxemia, describing criteria
for early diagnosis and developing new treatment ap-
proaches in order to decrease mortality [2, 3].
Intravenous choline administration show beneficial
effects in the treatment of endotoxemia [4–7] in vari-
ous species such as dogs and rats. Beneficial effects of
intravenous choline treatment are reported in association
with the activation of the efferent vagus nerve-based cho-
linergic anti-inflammatory pathway by the increase in nic-
otinic cholinergic neuro-transmission [5, 8] following
enhanced acetylcholine release by choline [9]. However
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the possible changes in serum proteins that choline treat-
ment can produce has not been studied.
Proteomics analysis allows the simultaneous analysis
of thousands of proteins in a sample. This could facili-
tate the identification of new biomarkers of use for
diagnosis and prognosis of sepsis/endotoxemia [10, 11].
Thus, proteomic analyses are a growing trend in human
[12] and veterinary medicine [13]. In particular prote-
omic studies allow identifying new proteins that change
in endotoxemia, and by knowing the function of these
new proteins, new mechanisms involved in endotoxe-
mia could be elucidated and therefore increase the
knowledge about its pathophysiology [14].
In the light of our previous findings [4–7], we
hypothesize that the beneficial effect of choline adminis-
tration in endotoxemic patients could be mediated by
changes in concentrations of selected serum proteins.
Therefore the objective of this study was to evaluate the
possible changes that can occur in serum proteins, by a
proteomic analysis, after endotoxin administration in
healthy and choline-treated calves.
Methods
Experimental set up
Healthy Holstein calves (4 weeks of age; 40 kg mean
weight; n = 20) were used in the present study. Their
health status was evaluated by clinical, haematological
and serum biochemical analyses. Calves were negative
for bovine herpes virus, bovine leucosis virus, brucel-
losis, bovine viral diarrhea, foot and mouth disease,
infectious bovine rhinotracheitis, paratuberculosis, and
tuberculosis when tested by commercial ELISA kits
(IDVet Diagnostics, Grabels, France).
Calves were randomized equally into 4 groups: Con-
trol, Choline treated (C), Lipopolysaccharide adminis-
tered (LPS), and LPS + C. Calves in the Control group
were injected with 0.9 % NaCl (saline; 5 ml, i.v.) twice
at an interval of 5 min while those in C group received
choline chloride (1 mg/kg, dissolved in 5 ml of saline,
i.v., once), 5 min after 0.9 % NaCl administration
(5 ml, i.v.). In the LPS group, endotoxin (LPS) was
injected (2 μg/kg, dissolved in 5 ml of normal saline,
i.v., once) to the calves, followed 5 min later by intra-
venous injection of normal saline. In LPS + C group,
endotoxin injection was followed 5 min later by cho-
line chloride injection at the doses described in the
LPS and C groups, respectively [15, 16].
Clinical data
Routine clinical examinations were performed before
(baseline) and 0.5–48 h after the treatments. A scoring
system adapted from a previous paper [17] was used to
evaluate clinical status in the study. Each parameter was
scored by minimum 0 point (means normal) to max-
imum 6 points (means severely affected).
Serum proteomic analysis
In order to analyse differences in protein expression in
the course of the study, three serum samples at each
time point for each treatment were obtained and the
protein profiles of the serum samples were analysed by
LC-MS/MS method [18–20]. Albumin depletion from
serum samples was done with albumin depletion spin
columns (Pierce, Thermo Scientific). IgGs from the
albumin-depleted serum samples were also depleted
with an Albumin/IgG Removal Kit (Pierce, Thermo sci-
entific). The remaining serum proteins (at same concen-
tration for all samples) were extracted and enzymatically
digested into peptides, and the resulting peptides were
subjected to the nanoUPLC-ESI-qTOF-MS system (nano-
ultra-performance LC and ESI quadrupole TOF MS)
(Waters) with the application of data independent ac-
quisition method also known as the MSE as previously
described in detail [20]. Minimum 3 technical replicates
for each sample were used for the analysis. The prote-
omic data was searched against a reviewed database [in-
cluding protein sequences of Bos taurus and an internal
standard (enolase, Saccharomyces cerevisiae; #P00924),
obtained from UniProt (htpp://www.uniprot.org)] with
previously described in silico parameters [19]. Quantitative
differences of proteins at different time points were calcu-
lated using Progenesis LC-MS software V4.0 (Nonlin-
ear Dynamics) [20].
Chemicals
Choline chloride and endotoxin (E. coli lipopolysacchar-
ide, LPS, serotype 055:B5) were purchased from Sigma
Chemical Co. (St. Louis, Missouri, USA).
Statistical analysis
Results were expressed as mean ± SEM. Data were evalu-
ated by one-way analysis of variance by repeated measures,
followed by Tukey test for pairwise comparisons. Clinical
scores were compared by a non-parametric test (Friedman
Repeated Measure ANOVA on Ranks). P values less than
0.05 were considered significant.
Results
Clinical data
Clinical findings are presented as Additional file 1
(Fig. 1). Briefly, choline induced a decrease in heart
and respiratory rates compared with the control ani-
mals. LPS administration increased body temperature
and heart and respiratory rates as compared to their
baselines. The severities of these changes in LPS + C
treatment were lower (p < 0.01) than those of calves
treated with LPS.
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Two calves died at 4 and 24 h after LPS and one at
48 h after LPS + C. Calves in control and choline groups
survived until the end of the study.
Serum proteins
Protein expression differences among experimental groups
at different time points (30 min, 1, 4 and 48 h) are shown
in Table 1. Details including numerical values for the
quantitative analysis obtained from the Progenesis LC-MS
software are shown in Additional file 1.
A total of 76 proteins were identified across the serum
samples by the proteomic analysis. After LPS adminis-
tration, 14 proteins increased, whereas 13 proteins
decreased within 48 h as compared to controls (Table 1).
In LPS group, there was a dramatic increase (189 fold, at
24 h) in ragulator complex protein LAMTOR2 which
was followed by other proteins showing changes ranging
from 6 to 13 fold such as negative elongation factor E
(at 4 h), galectin-3 binding protein (Gal-3BP), arginino-
succinate lyase and membrane primary amine-oxidase
(at 48 h). Following LPS administration, moderate de-
creases (< 5 fold changes) were observed in some pro-
teins such as serpin A3-4 (at 30 min.), vitamin D
binding protein (VDBP), inter alpha trypsin inhibitor
heavy chain H3 (ITIH, at 4 h), apolipoprotein A IV
(Apo-AIV), alpha-1B glycoprotein and serotransferrin
A B
C D
Fig. 1 Clinical parameters (a, temperature; b-c, heart and respiratory rates; and d, total clinical score) in saline, choline, LPS and LPS + choline
groups. Calves were injected i.v. once with saline (5 ml) or saline containing choline chloride (1 mg/kg). Five minutes after the first i.v. treatment,
calves received endotoxin (LPS, 2 μg/kg) in 5 ml normal saline. Measurements were performed immediately before first i.v. treatment (0 h) and 1 – 48 h
after saline, choline, LPS or LPS + choline treatments. Each point represents to Mean ± SEM of six determinations. * p < 0.05, **p < 0.001, ***p < 0.001 as
compared to baseline + p < 0.05, ++p < 0.01 as compared to saline group
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Table 1 Protein expression differences among experimental groups at different time points (30 min, 1 h, 4 h and 48 h)
LPS_Choline P02081; Hemoglobin fetal subunit
beta/1.52
Q9QAQ7; Non structural protein of
4 9 kDa/3.42
P02676; Fibrinogen beta chain/3.83
A2I7N1; Serpin A3 5/1.44
Q3ZC07*; Actin alpha cardiac muscle 1/15.21
Q32L76; Serum amyloid A 4 protein/1.70
A2I7N3; Serpin A3 7/1.44
Q3ZC07*; Actin alpha cardiac muscle 1/187.33
P0CH28*; Polyubiquitin C/1.59
P12799; Fibrinogen gamma B chain/8.44
Q2M2T2; U-p-C19orf71-h/2.17
P02676; Fibrinogen beta chain/64.53
A2I7N1; Serpin A3 5/1.44
Q9TTK6; Membrane primary amine
oxidase/Infinity
P01966; Hemoglobin subunit alpha/1.50
P19034; Apolipoprotein C II/2.82
Q9MYP6; beta hydroxysteroid dehydrogenase
14/26.44
Q1JQ97; Bardet Biedl syndrome 4 protein
homolog/2.30
Q9TTK6; Membrane primary amine oxidase/11.79
P81644; Apolipoprotein A II/1.45
P19035; Apolipoprotein C III/2.34
Q32L76; Serum amyloid A 4 protein/2.20
Q5E9E3; Complement C1q subcomponent
subunit A/3.01
P34955; Alpha 1 antiproteinase/1.60
P28800; Alpha 2 antiplasmin/1.43
P80012; von Willebrand factor Fragment/2.98
Q9TTE1; Serpin A3 1/2.09
Q80E01; Glutaredoxin 1/2.21
Q3SZJ0; Argininosuccinate lyase/1.81
Q17QL1; Glucosamine 6 phosphate
isomerase 2/2.96
Q3T0Z5; Leukocyte receptor cluster
m-1-h/2.22
Q9TTE1; Serpin A3 1/1.74
Q9TTK6; Membrane primary amine
oxidase/64.58






Q0V898; Negative elongation factor E/1.68
Q9TTK6; Membrane primary amine
oxidase/7.17
A6QPQ2; Serpin A3 8/1.67
O46406; Primary amine oxidase lung
isozyme/3.74
P01044; Kininogen 1/2.13
A7E3W2; Galectin 3 binding protein/13.09
P41356; Fusion glycoprotein F0/1.82
O62830-2; Isoform Beta 2 of Protein
phosphatase 1B/6.78
Q3T132; Ragulator complex protein
LAMTOR2/189.56
Q3SZJ0; Argininosuccinate lyase/9.22
Q9QAQ7; Bovine coronavirus strain OK 0514
GN 4a/4.93
Q0V898; Negative elongation factor E/10.86
Q28901;6-p-2-k-f-2-6-b-f/Infinity
A2I7N2; Serpin A3 6/1.64
P81644; Apolipoprotein A II/1.62
P19035; Apolipoprotein C III/2.80
Q5E9E3; Complement C1q subcomponent
subunit A/2.66
Q28901; 6-p-2-k-f-2-6-b-f/infinity
P01966; Hemoglobin subunit alpha/1.81




Q7SIH1; Alpha 2 macroglobulin/1.41
A2I7M9; Serpin A3 2/9.68
P00924; ENO1 YEAST Enolase 1/1.46
Q3MHN5; Vitamin D binding protein/1.67
Q3ZC07*; Actin alpha cardiac muscle 1/25.52
P80109; Phosphatidylinositol glycan specific
phospholipase D/3.11
O02659; Mannose binding protein C/5.76
P0CH28*; Polyubiquitin C/4.09
A8YXX7; Trefoil factor 3/4.93
Q2TBS3; Uncharacterized protein C20orf79
homolog/4.76
Q96629; Adenain/2.23
P19034; Apolipoprotein C II/4.21
Q1JP73; UPF0553 protein C9orf64 homolog/12.57
Q9TTK6-2; Isoform 2 of Membrane
primary amine oxidase/2.30
Q1JP73; UPF0553 protein C9orf64
homolog/1.95
Q56K14; 60S acidic ribosomal protein
P1/Infinity
Q3SZV7; Hemopexin/2.10
Q1JQ97; Bardet Biedl syndrome 4
protein homolog/1.48
Q56K14;60S acidic ribosomal protein
P1/Infinity
Q96629; Adenain/1.74
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A2I7N3; Serpin A3 7/1.56
Q17QL1; Glucosamine 6 phosphate
isomerase 2/1.48






Q05204; Lysosome associated membrane
glycoprotein 1/4.03
Q56K14; 60S acidic ribosomal protein
P1/8968.4
P34955; Alpha 1 antiproteinase/1.47
A2I7N2; Serpin A3 6/1.72
Q3SZJ0; Argininosuccinate lyase/1.41
Q17QL1; Glucosamine 6 phosphate
isomerase 2/8.44
Control P80012; von Willebrand factor Fragment/2.08 A2I7N0; Serpin A3 4/1.60 P21752; Thymosin beta 10/1.45




Q3T132; Ragulator complex protein
LAMTOR2/2.04
Q05204; Lysosome associated membrane
glycoprotein 1/2.34
P01044-2*; Isoform LMW of Kininogen
1/2.87
Q9TTK6-2; Isoform 2 of Membrane primary
amine oxidase/2.82
Q80E01; Glutaredoxin 1/3.37 Q58CQ9; Pantetheinase/1.58
Q05204; Lysosome associated membrane
glycoprotein 1/10.89
Q3MHN5; Vitamin D binding protein/1.48
Q96629; Adenain/1.69
Q2KIU3; Protein HP 25 homolog 2/1.70 P56652; Inter alpha trypsin inhibitor heavy chain
H3/1.58
P02081; Hemoglobin fetal subunit beta/1.72 Q29443; Serotransferrin/1.57 P01044-2*; Isoform LMW of Kininogen
1/1.62
Q32PJ2; Apolipoprotein A IV/1.45 Q58CQ9; Pantetheinase/1.84
A2I7N2; Serpin A3 6/4.57 P21752; Thymosin beta 10/1.46
Q2KJF1; Alpha 1B glycoprotein/1.46 Q9MYP6;17 beta hydroxysteroid
dehydrogenase 14/2.24
P01966; Hemoglobin subunit alpha/1.63
P02070; Hemoglobin subunit beta/1.98
A7YY73; Transcription factor MafF/5.00
E1BF81; Corticosteroid binding
globulin/5.27
Control Choline LPS LPS_Choline
This table shows the identified proteins with highest mean condition (left) and lowest mean condition (bottom) among experimental groups at different time points at statistically significant level (P < 0.05). Relative
abundance levels of the proteins with highest mean condition, compared to the proteins with lowest mean condition, are indicated after the slash (/). Time points are indicated with underline, italic and italic + underline, for
1 h, 4 h and 48 h time points, respectively. Asterisk (*) indicates the proteins, of which, isoforms are detectable (see Additional file for the accession numbers of the isoforms). Abbreviations; c. e.: conjugating enzyme, 6-p-2-k-f-














(at 48 h). In addition more prominent decreases (≥ 5 fold
changes, at 48 h) were observed in transcription factor
MafF and corticosteroid binding globulin (CBG).
When compared with LPS group, in LPS + C group,
glucosamine-6-phosphate isomerase-2, membrane primary
amine oxidase, fibrinogen gamma B chain, antithrombin
and prothrombin were markedly up-regulated, while iso-
form 2 of membrane primary amine oxidase, hemopexin
and histone-H4 were markedly down-regulated. Actin
alpha cardiac muscle-1 expression increased at 1–48 h
(15–187 fold) in LPS and LPS + C groups, as compared
to controls. The magnitude of increase in actin alpha
cardiac muscle-1 was lower at 48 h in LPS + C group
than that of LPS group. As compared to controls, fol-
lowing choline administration, a number of proteins
(primary amine oxidase, serpin A3-7 and glucosamine-
6-phosphate isomerase-2) were up-regulated while
others (lysosome associated membrane glycoprotein-1
and glutaredoxin-1) were more down-regulated at dif-
ferent time points of the study.
Discussion
In this study, an experimental model consisting in the
induction of endotoxemia by LPS administration in
calves was chosen, because calves are very sensitive to
LPS. Therefore is expected that the changes associated
with LPS as well as its treatment will be easier to detect
than with other animal models. The clinical changes oc-
curred after LPS treatment in our experimental model in
calves showed similarities with the results of experimen-
tal human [21] and animal studies of sepsis/endotoxemia
[4–7, 15–17].
To our knowledge, our study describes for the first
time 14 proteins that are up-regulated, and 13 proteins
that are down-regulated in endotoxemia in calves. The
roles of some of these altered proteins are highlighted
below.
One of the proteins that were dramatically up-regulated
was ragulator complex protein LAMTOR2. This protein
is known to be involved in amino acid sensing and activa-
tion of mTORC1 [22], a signalling complex promoting cell
growth in response to growth factors, energy levels, and
amino acids. A previous study reported that severe im-
munological defects affecting the immunity in human
primary immunodeficiency syndrome was associated
with reduced levels of LAMTOR2 [22]. Hence, the ele-
vated serum levels of ragulator complex in our study
may be associated with host’s response by increasing
macrophage activity and enhancing adaptive immunity
in response to LPS. Thus, ragulator complex may rep-
resent a new early diagnostic marker for the detection
of inflammation in calves, due to its dramatic overex-
pression shortly after LPS treatment.
Another protein, which significantly increased in calves
after LPS administration, was Gal-3BP. This protein has
stimulatory activity on lymphokine-activated and natural
killer cells, and also stimulates the secretion of many cyto-
kines and interleukins in peripheral blood mononuclear
cells that all play a contributory role in inflammation [23].
In this study, up-regulated expression of Gal-3BP may
be associated with limiting an on-going inflammation
in response to LPS, because of its immune modulatory
activity [23]. In addition, overexpressed Gal-3BP may
be considered as a host response to neutralize harmful
effects of Galectin-3 which is released from LPS-
stimulated cells to produce heightened levels of inflam-
matory mediators, resulting in further tissue damage
and, ultimately, organ failure, characteristics of sepsis.
On the other hand, Gal-3BP has a critical role in the
development of venous thrombosis [24] and to increase
the survival of cancer cells in the bloodstream [25], in-
dicating that probably is involved in the pathophysio-
logical responses of different pathological conditions.
Transcription factor MafF and CBG are associated
with interleukin regulation [26], and have a protective
effect in situations of cell stress, coagulation cascade ac-
tivation and severe illness [27]. A possible reason for the
down regulations of these proteins found in our study
may be excessive use of them to neutralize detrimental
effects of LPS during acute phase reaction.
Proteases from LPS-activated leukocytes can trigger
tissue and organ damage and enhance the nonspecific
proteolysis of plasma clotting factors in patients with se-
vere sepsis. One example is the leukocyte elastase that is
involved in the progress of complications in patients
with sepsis [28]. In the present study, down regulation of
ITIH-H3 in calves with LPS was most probably due to
extended secretion of elastase [28], thereby this protein
may be a part of the regulatory system that controls
acute inflammation [29] in calves. Similar to our finding,
circulating ITIH protein level was found lower in pa-
tients with severe sepsis than in healthy volunteers [28].
Confirming our previous findings in dogs and rats
[4–7], we found in the present study that choline treat-
ment improved the clinical signs associated to LPS.
Further studies including larger number of calves are
needed to evaluate if choline treatment could reduce
mortality rate in this clinical condition. Endotoxemia
studies in dogs showed that these beneficial effects of
choline treatment might be related with inhibition of
TNF-α synthesis [4], prevention of hepato-renal injury
[4], and attenuation of the changes of serum butrylcho-
linesterase and paraoxonase-1 activities [30].
Most of the down-regulated proteins after choline
treatment such as kininogen-1, prothrombin, and ragula-
tor complex are involved in coagulation and the devel-
opment of DIC. Therefore the decrease of these proteins
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could be associated with the preventive effects of cho-
line treatment on the development of coagulopathy, as
described previously in dogs [7]. In addition the down-
regulation of histones after choline treatment would be
related with the protective effect of choline. Histone
proteins, mainly the histones-H3 and H4, have been re-
ported to exhibit cytotoxicity when released to the
extracellular fluid in response to severe stress or in-
flammatory challenges like sepsis and to mediate exces-
sive and overwhelming cell damage and death [31].
Hemopexin (Hx) is mainly expressed as an APP from
liver after inflammation [32]. In this study, Hx overex-
pression may be related with its antioxidant role [32]
to facilitate tissue repair in response to LPS [33]. Cho-
line treatment decreased Hx overexpression in calves
with LPS, probably related with the reduction in body’s
antioxidant needs [32, 34] due to the reduction in tis-
sue damage produced by choline [3].
The increase found in SAA4 after choline administra-
tion could be related with the protective effect that has
been described for SAA by inhibiting TNF and LPS as
well as platelet aggregation [35]. In addition a correl-
ation between SAA4 and cholinesterase has been found,
therefore a link between SAA4 response and choline ad-
ministration could be hypothesized [36].
Choline treatment attenuated overexpression of con-
tractile protein actin alpha cardiac muscle-1 (ACTC1) at
48 h after LPS, indicating a protective effect of choline
treatment on sepsis-induced myocardial dysfunction
(SIMD). SIMD is a well-recognized manifestation of
organ dysfunction in patient with sepsis [37] and calves
with endotoxemia [38]. LPS-induced overexpression of
ACTC1 may contribute to myocardial dysfunction dur-
ing endotoxemia [39], most probably due to impaired
sarcomere integrity [40]. The observed overexpression of
ACTC1 may be due to decreased thymosin beta-10
expression since thymosin beta-10 plays an important
role in the organization of the cytoskeleton by binding
to and sequestering actin monomers resulting with an
inhibition in actin polymerization [41].
Conclusion
Although this is a pilot study made with a small sam-
ple size and therefore the results should be taken with
caution. It could be concluded that based on our ex-
perimental model, following LPS administration, there
are changes in selected serum proteins which are asso-
ciated with various biological processes such as lipid
metabolism, immune and inflammatory response, pro-
tein binding and transport, cell adhesion, venous
thrombosis, cardiac contraction and blood coagula-
tion. In addition choline administration is associated
with changes in serum concentrations of selected serum
proteins that would be related with its beneficial effect in
this clinical situation. These findings would reinforce the
effectiveness of choline administration in the treatment of
endotoxemia. However further studies are needed to con-
firm our results due to small sample size of this study, and
in addition it would be interesting to evaluate the effect-
iveness of choline treatment in combination with other
drugs such as steroidal or non-steroidal anti-inflammatory
drugs.
Additional file
Additional file 1: Clinical parameters (temperature, heart and respiratory
rates, and total clinical score) in all groups. (XLSX 109 kb)
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